Systemic Delivery of CpG Oligonucleotides

CpG 寡核苷酸的全身递送

基本信息

  • 批准号:
    7524167
  • 负责人:
  • 金额:
    $ 30.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-16 至 2013-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Bacterial extracts often show anti-tumor effect. It was only recently discovered that the active component in the ill-defined cancer treatment is bacterial DNA, not protein, carbohydrate, or lipid. In contrast to human genomic DNA, bacterial DNA shows unmethylated cytidine-guanidine dinucleotide sequences, commonly referred to as CpG. Our own body's host defense system has evolved such a way that whenever CpG is found in the body, it serves as a "danger" signal. Resulting innate immunity can be harnessed to fight against tumor growth. Most attractively, once tumor-associated antigens are shed from the tumor, dendritic cells activated by CpG can process them and present to T lymphocytes that can kill the tumor cells. In short, CpG-based immunotherapy can exploit not only its innate immune response but also subsequent adaptive immune response. Thus CpG has become one of the most exciting immunotherapies in recent years. However, the approach works only with intra-tumoral or peri-tumoral route of administration in animal models. In Phase II human studies, intravenous route was ineffective while subcutaneous administration produced only minor effects. Taken together these rather disappointing outcomes can be attributed to poor delivery of the CpG in vivo. Recently we were able to demonstrate a way to circumvent this critical problem in delivery. Our approach was based on the fact that immune complexes can circulate in the blood for a long time so long as they do not trigger antigen crosslinking. In tumor-bearing mice our formulation showed a half-life of several days in the blood and as much as 20% of the dose accumulated in tumor tissue. In accordance with this favorable pharmacokinetic, intravenously administered CpG successfully retarded solid tumor growth. More recently we also discovered that a subcutaneous route was as effective. We have our own explanations of these exciting results and this proposal is designed to test these hypotheses. This portion constitutes one aspect of the proposal. The other portion of the proposal is concerned with development of two new systems that will not require a step that may be acceptable in animal studies but may not be in humans. Successful outcome of the proposed studies will undoubtedly accelerate CpG-based immunocancer therapy and will provide another viable option in treating cancer along with other existing treatments. Public Health Relevance: It has been known for many years that bacterial DNA fragments exert anti-tumor effect. To be effective, they must be introduced where tumor is growing. This proposal deals with strategies for developing a convenient intravenous or subcutaneous route of administration that will deliver the agents to the tumor tissue.
描述(由申请人提供):细菌提取物通常显示抗肿瘤作用。直到最近才发现,这种定义不清的癌症治疗中的活性成分是细菌DNA,而不是蛋白质、碳水化合物或脂质。与人类基因组DNA相反,细菌DNA显示未甲基化的胞苷胍二核苷酸序列,通常称为CpG。我们自己身体的宿主防御系统已经进化成这样一种方式,每当在体内发现CpG时,它就作为一个“危险”信号。由此产生的先天免疫可以用来对抗肿瘤生长。最吸引人的是,一旦肿瘤相关抗原从肿瘤中脱落,由CpG激活的树突细胞可以处理它们并呈递给T淋巴细胞,T淋巴细胞可以杀死肿瘤细胞。简而言之,基于CpG的免疫疗法不仅可以利用其先天免疫应答,还可以利用随后的适应性免疫应答。因此,CpG已成为近年来最令人兴奋的免疫疗法之一。然而,该方法仅适用于动物模型中的肿瘤内或肿瘤周围给药途径。在II期人体研究中,静脉途径无效,而皮下给药仅产生轻微影响。总之,这些相当令人失望的结果可归因于CpG在体内的不良递送。最近,我们能够展示一种方法来规避交付中的这一关键问题。我们的方法是基于这样一个事实,即免疫复合物可以在血液中循环很长一段时间,只要它们不触发抗原交联。在荷瘤小鼠中,我们的制剂在血液中的半衰期为几天,在肿瘤组织中累积的剂量高达20%。根据这种有利的药代动力学,静脉内施用CpG成功地延缓了实体瘤生长。最近,我们还发现皮下途径同样有效。我们对这些令人兴奋的结果有自己的解释,这个提议旨在测试这些假设。这一部分是提案的一个方面。提案的另一部分涉及开发两种新系统,这两种系统不需要在动物研究中可以接受但在人类中可能不可接受的步骤。所提出的研究的成功结果无疑将加速基于CpG的免疫癌症治疗,并将与其他现有治疗一起沿着治疗癌症提供另一种可行的选择。 公共卫生相关性:多年来人们已经知道细菌DNA片段具有抗肿瘤作用。为了有效,它们必须被引入肿瘤生长的地方。该建议涉及开发将药剂递送至肿瘤组织的方便的静脉内或皮下施用途径的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MOO J CHO其他文献

MOO J CHO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MOO J CHO', 18)}}的其他基金

Systemic Delivery of CpG Oligonucleotides
CpG 寡核苷酸的全身递送
  • 批准号:
    8074537
  • 财政年份:
    2008
  • 资助金额:
    $ 30.15万
  • 项目类别:
Systemic Delivery of CpG Oligonucleotides
CpG 寡核苷酸的全身递送
  • 批准号:
    8260573
  • 财政年份:
    2008
  • 资助金额:
    $ 30.15万
  • 项目类别:
Systemic Delivery of CpG Oligonucleotides
CpG 寡核苷酸的全身递送
  • 批准号:
    7659407
  • 财政年份:
    2008
  • 资助金额:
    $ 30.15万
  • 项目类别:
Systemic Delivery of CpG Oligonucleotides
CpG 寡核苷酸的全身递送
  • 批准号:
    7845014
  • 财政年份:
    2008
  • 资助金额:
    $ 30.15万
  • 项目类别:
pH- SENSITIVE BIS-DETERGENTS FOR MACROMOLECULAR DELIVERY
用于大分子输送的 pH 敏感双去污剂
  • 批准号:
    6776804
  • 财政年份:
    2004
  • 资助金额:
    $ 30.15万
  • 项目类别:
pH- SENSITIVE BIS-DETERGENTS FOR MACROMOLECULAR DELIVERY
用于大分子输送的 pH 敏感双去污剂
  • 批准号:
    6872986
  • 财政年份:
    2004
  • 资助金额:
    $ 30.15万
  • 项目类别:
TARGETING ENDOGENOUS ANTIBODIES TO OVARIAN CARCINOMA
针对卵巢癌的内源性抗体
  • 批准号:
    6623365
  • 财政年份:
    2002
  • 资助金额:
    $ 30.15万
  • 项目类别:
TARGETING ENDOGENOUS ANTIBODIES TO OVARIAN CARCINOMA
针对卵巢癌的内源性抗体
  • 批准号:
    6465181
  • 财政年份:
    2002
  • 资助金额:
    $ 30.15万
  • 项目类别:
ASSAY SYSTEM FOR EVALUATING CELLULAR ANTISENSE DELIVERY
用于评估细胞反义递送的测定系统
  • 批准号:
    2900929
  • 财政年份:
    1998
  • 资助金额:
    $ 30.15万
  • 项目类别:
ASSAY SYSTEM FOR EVALUATING CELLULAR ANTISENSE DELIVERY
用于评估细胞反义递送的测定系统
  • 批准号:
    2602743
  • 财政年份:
    1998
  • 资助金额:
    $ 30.15万
  • 项目类别:

相似海外基金

Disentangling Genetic and Experiential Risk Factors for Cortical Abnormalities in a Mouse Model of Schizophrenia
解开精神分裂症小鼠模型皮质异常的遗传和经验危险因素
  • 批准号:
    MR/Y014693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.15万
  • 项目类别:
    Research Grant
Validation of the joint-homing and drug delivery attributes of novel peptides in a mouse arthritis model
在小鼠关节炎模型中验证新型肽的关节归巢和药物递送特性
  • 批准号:
    10589192
  • 财政年份:
    2023
  • 资助金额:
    $ 30.15万
  • 项目类别:
Recruitment of Cerebellar Circuits with Balance Training for Cognitive Rehabilitation in a Mouse Model of Mild Traumatic Brain Injury
在轻度创伤性脑损伤小鼠模型中通过平衡训练募集小脑回路进行认知康复
  • 批准号:
    10753349
  • 财政年份:
    2023
  • 资助金额:
    $ 30.15万
  • 项目类别:
A mouse model of relapsing polychondritis by utilizing matrilin-1 peptides
利用 matrilin-1 肽建立复发性多软骨炎小鼠模型
  • 批准号:
    23K05618
  • 财政年份:
    2023
  • 资助金额:
    $ 30.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
  • 批准号:
    23K06731
  • 财政年份:
    2023
  • 资助金额:
    $ 30.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of molecular mechanisms of kidney cancer development by epigenetic mutations in a mouse model.
通过小鼠模型的表观遗传突变分析肾癌发生的分子机制。
  • 批准号:
    23K15771
  • 财政年份:
    2023
  • 资助金额:
    $ 30.15万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Cellular and circuit function of Ndnf-expressing interneurons in a mouse model of a neurodevelopmental disorder
神经发育障碍小鼠模型中表达 Ndnf 的中间神经元的细胞和回路功能
  • 批准号:
    10678812
  • 财政年份:
    2023
  • 资助金额:
    $ 30.15万
  • 项目类别:
A Mouse Model to Test the Effects of Gender-affirming Hormone Therapy on HIV Vaccine-induced Immune Responses
测试性别肯定激素疗法对 HIV 疫苗诱导的免疫反应影响的小鼠模型
  • 批准号:
    10748892
  • 财政年份:
    2023
  • 资助金额:
    $ 30.15万
  • 项目类别:
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
  • 批准号:
    23K08467
  • 财政年份:
    2023
  • 资助金额:
    $ 30.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Deconstructing epileptic circuits in a mouse model of SLC6A1 syndrome
解构 SLC6A1 综合征小鼠模型中的癫痫回路
  • 批准号:
    10508480
  • 财政年份:
    2023
  • 资助金额:
    $ 30.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了